Title : Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.

Pub. Date : 2019

PMID : 31890041






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: Evogliptin (EVO) is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP4i) developed for the treatment of type 2 diabetes mellitus (T2DM). 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one dipeptidyl peptidase 4 Homo sapiens